Submission on proposal to decline some medicine applications on the Options for Investment list

Rare Disorders NZ has made a submission on the proposal to decline some medicine funding applications on the Options for Investment list.

RDNZ strongly opposes Pharmac’s proposal to decline some medicine funding applications on the Options for Investment (OFI) list. The current lack of transparency around the ranking of medicines on the OFI list is unacceptable and must be addressed. However, RDNZ strongly disagrees that removing the bottom 10 to 20 percent of the lowest ranked medicines from the OFI list is the right way to achieve the stated goal of creating greater transparency and clarity to how medicine funding applications are managed on the OFI.

Read our full submission here.

Collective statement

Rare Disorders NZ also endorsed, along with 51 other consumer and patient representative groups, a joint statement opposing Pharmac’s proposal to decline some medicine funding applications on the Options for Investment list.

Read the full statement here.